Cornerstones of a well-designed phase III trial

被引：1

作者：

Buyse, M ^{[1
]}

机构：

[1] IDDI, B-1050 Brussels, Belgium

来源：

EJC SUPPLEMENTS | 2003年 / 1卷 / 06期

关键词：

D O I：

10.1016/S1359-6349(03)90011-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：67 / 75

页数：9

共 21 条

[1]

Abe O, 1998, LANCET, V352, P930

[2]

[Anonymous], 2002, Data monitoring committees in clinical trials: A practical perspective

[3]

[Anonymous], 1999, GROUP SEQUENTIAL MET

[4]

[Anonymous], 2000, Applied Clinical Trials

[5] Subgroup analysis and other (mis)uses of baseline data in clinical trials [J].

Assmann, SF ;

Pocock, SJ ;

Enos, LE ;

Kasten, LE .

LANCET, 2000, 355 (9209) :1064-1069

[6]

Baum M, 2002, LANCET, V359, P2131

[7] Influence of unrecognized molecular heterogeneity on randomized clinical trials [J].

Betensky, RA ;

Louis, DN ;

Cairncross, JG .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (10) :2495-2499

[8]

Bloom JC., 2003, BIOMARKERS CLIN DRUG

[9] Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis [J].

Buyse, M ;

Thirion, P ;

Carlson, RW ;

Burzykowski, T ;

Molenberghs, G ;

Piedbois, P .

LANCET, 2000, 356 (9227) :373-378

[10] Should Dukes' B patients receive adjuvant therapy? A statistical perspective [J].

Buyse, M ;

Piedbois, P .

SEMINARS IN ONCOLOGY, 2001, 28 (01) :20-24

← 1 2 3 →